Myriad Genetics Inc (MYGN) Directors and Executive Officers

Officers & Directors

Paul J. Diaz
President and Chief Executive Officer

S. Louise Phanstiel
Chair of the Board

Heiner Dreismann
Director

Natalie Munk
Director

Daniel K. Spiegelman
Director

Paul Bisaro
Director

Rashmi Kumar
Director

Scott J. Leffler

Colleen F. Reitan
Director

Daniel M. Skovronsky
Director

Lee N. Newcomer
Director ,

Myriad Genetics Inc currently has 2700 employees.

News about Myriad Genetics Inc Key Personnel

Myriad Genetics Announces Leadership Transition and Collaborates with Diligent for Enhanced Governance Practices

In a significant development poised to shape the future trajectory of corporate governance and risk management, Myriad Genetics has announced a transition in its senior leadership. Effective April 30, 2025, Sam Raha will assume the role of Chief Executive Officer, while Mark S. Verratti steps in as Chief Operating Officer. This strategic shift highlights the company’s commitment to innovation and excellence as it navigates the complexities of the healthcare landscape.This leadership change at Myriad Genetics comes at a time of noteworthy transformation within the realm of governance, risk, and compliance (GRC). The necessity for effective governance frameworks has never been more pronounced, with companies...

Myriad Genetics Appoints Renowned Physician to Lead Women's Health Division Amidst Company Challenges

In a move aimed at bolstering its position in the field of genetic testing and precision medicine, Myriad Genetics, Inc. (NASDAQ: MYGN) has appointed esteemed physician Dr. Dallas Reed as the Principal Medical Advisor to its women s health business unit. Effective immediately, Dr. Reed s appointment is seen as a strategic decision by the company to navigate through the challenges it has been facing.
Myriad Genetics, a leading player in the genetic testing industry, has witnessed a dip in its share value with a 1.8% decrease recorded in February 2024. This decline comes as the company s cumulative net loss for the 12-month period ending in the third quarter of 2023 amounted to a staggering $-274...